SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT07344922
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT07344922
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT07344922. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2023-11-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
- Condition
- Chronic Kidney Disease
- Condition
- Anemia
- Condition
- Cardiovascular Calcification
- Intervention (Drug)
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Intervention (Other)
- Placebo
- Lead sponsor
- Mansoura University
Record details
- Record id
cardio:ct-nct07344922- Content hash
726e8c121ea47298dd7a11c7540e2067ca4febed9afa8775be97b31b65904b4c